AbbVie (ABBV)

These companies are committed to rewarding shareholders.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...

AbbVie's market-beating days don't seem to be over yet.

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

The company is still looking to bounce back after the beating it took in recent years.

It is certainly a good Dividend King to buy in September.

These three stocks meet multiple criteria for long-term dividend investing success.

AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E

Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.

AbbVie's dividend is a very appealing factor.

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.17% on an annualized basis producing an average annual return of 14.76%. Currently, AbbVie has a market capitalization of $445.73 billion.

AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i

These two are on the Dividend Kings list.

Dividend seekers can hardly go wrong with these companies.

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Low-cost index funds can be a ticket to prosperity for everyday investors.

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Owning these dividend stocks could be a simple way to make money over the long term.

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of $468.74 billion.

His AbbVie purchase was a big move into a high-yielding dividend stock.